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Menopause is a condition where severe depletion of estrogen levels leads to a cluster of adverse 
symptoms such as anxiety, cutaneous vasodilation/sudomotor "hot flashes", sleep disturbances, and 
appetite change (Freeman et al., 2005; Seritan et al., 2010). Previously, estrogen replacement therapy 
was the first line treatment for menopausal symptoms. However, it is no longer acceptable due to 
increased risk of cancer (Rossouw et al., 2002). Therefore there is a need for creating non-hormonal 
therapies to reduce the incidence of adverse menopausal-related symptoms. This is hindered by the 
limited understanding of menopausal symptoms and a lack of animal models of "hot flashes" (Nelson et 
al., 2006). Currently, the most accepted model of hot flashes is addicting female rats to morphine then 
inducing morphine withdrawal using naloxone (a ?-opioid receptor competitive antagonist) to provoke 
increases in tail temp (an indicator of cutaneous vasodilation). Yet, there is no evidence that the opioid 
system is disrupted in women with menopause [e.g., naloxone does not provoke "hot flashes" clinically 
(DeFazio et al., 1984)]. Here we induced a menopausal state by surgically removing the ovaries (OVEX) 
to deplete estrogen which induces a cluster of adverse menopause-like symptoms that include: 1) 
increased anxiety; 2) weight gain; and 3) disrupted diurnal skin and core body tempature changes. 
Additionally, we have developed an alternative model of "hot flashes" where administering yohimbine 
(an alpha2-adrenergic autoreceptor antagonist that provokes "hot flashes in menopausal women) 
resulted in "hot flash"-related increases in skin temp in OVEX, but not sham-OVEX, female rats. 
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